Opus Genetics Short Interest Rises 17.9% in February

Biotech firm sees increased short selling activity as analysts maintain buy ratings

Mar. 17, 2026 at 1:24am

Got story updates? Submit your updates here. ›

Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage ophthalmic biopharmaceutical company, saw a 17.9% increase in short interest during February, reaching 1,110,696 shares or 1.7% of the company's total shares outstanding. The days-to-cover ratio, based on the stock's average daily trading volume, currently stands at 1.3 days.

Why it matters

The rise in short interest could indicate increased bearish sentiment among investors towards Opus Genetics, despite the company receiving positive analyst coverage with several "buy" ratings. Short selling activity can be a signal of market skepticism about a company's prospects, though it does not necessarily reflect the long-term fundamentals.

The details

Opus Genetics, which focuses on developing therapies for refractive and retinal eye disorders, has seen its stock price rise in recent months. The company has received positive analyst coverage, with Lifesci Capital upgrading the stock to a "strong-buy" rating and several other firms initiating coverage with "buy" recommendations and price targets ranging from $7 to $11.

  • As of February 27th, 2026, Opus Genetics had 1,110,696 shares sold short.
  • This represents a 17.9% increase from the 942,054 shares sold short as of February 12th, 2026.

The players

Opus Genetics, Inc.

A clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for refractive and retinal eye disorders.

Lifesci Capital

An investment research firm that upgraded Opus Genetics to a "strong-buy" rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

The rise in short interest in Opus Genetics could signal increased market skepticism about the company's prospects, despite positive analyst coverage and a recent stock price increase. Investors will likely continue to monitor the company's progress and any further changes in short interest activity.